



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

						
	Complete if Krown					
Application Number	Unassigned 17 2 3 9 6					
Filing Date	Herewith					
First Named Inventor	BOYD et al.					
Group Art Unit	Unassigned					
Examiner Name	Unassigned					
Attorney Docket Number	231119					

				U.S. PATENT DOCUMENTS		
		U.S. Patent Do	cument			
Examiner Doc. Initials No.	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
ZL	AA	5,314,995		Fell, Jr. et al.	May 24, 1994	
	AB	5,821,081		Boyd et al.	Oct. 13, 1998	
	AC	5,843,882	1	Boyd et al.	Dec. 1, 1998	
	AD	5,962,653		Boyd et al.	Oct. 5, 1999	
	ΑE	5,962,668		Boyd et al.	Oct. 5, 1999	
	AF	5,998,587		Boyd et al.	Dec. 7, 1999	
	AG	6,015,876		Boyd	Jan. 18, 2000	
V	АН	6,245,737	B1	Boyd et al.	Jun. 12, 2001	
ZL	AI	6,428,790	B1	Boyd	Aug. 8, 2002	·

				FORE	IGN PATENT DOCUMENTS			
		F	oreign Patent Docume	nt			. Trans	lation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
ZL	AJ	wo	93/06216		Oklahoma Medical Research Foundation	Apr. 1, 1993		

Examiner Doc.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	lation
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**
7.1	AK	AGNEW et al., Sex. Trans. Dis., 22(5), 269-273 (1995)		
	AL	AMON et al., The Plant Cell, 10, 781-789 (1998)		
	AM	ANDORFER et al., J. Insect Phys., 46, 365-372 (2000)		
	AN	ANDREU et al., J. Infect. Dis., 171, 1237-1243 (1995)		
	AO	AULLO et al., EMBO J., 11(2), 575-583 (1992)		
	AP	BALZARINI et al., Antiviral Res., 18, 191-207 (1992)		
	AQ	BERZOFSKY, J. Acquired Immune Deficiency Syndromes, 4, 451-459 (1991)		
	AR	BOLMSTEDT et al., Mol. Pharmacology, 59(5), 949-954 (2001)		
	AS	BOYD et al., Antimicrob. Agents Chemother., 41(7), 1521-1530 (1997)		
	AT	BOYD, AIDS Etiology, Diagnosis, Treatment, and Prevention, 2 nd Ed., 305-317 (1988)		
	ΑU	BOYD et al., J. Med. Chem., 37, 1740-1745 (1994)		
	AV	BRUCE et al., Can. J. Microbiol., 34, 339-343 (1988)		
	AW	BUCKHEIT et al., Antiviral Res., 21, 247-265 (1993)		
	AX	CAMMACK, Curr. Opin. Infect. Dis., 14, 13-16 (2001)		
	AY	CAPON et al., Annu. Rev. Immunol., 9, 649-678 (1991)		
	AZ	CAPON et al., Nature, 337, 525-531 (1989).		
	ВА	CARONE et al., J. Lab. Clin. Med., 100(1), 1-14 (1982)		
	BB	CARTER et al., J. Org. Chem., 49, 236-241 (1984)		
	ВС	CHARAN et al., J. Nat. Prod., 63, 1170-1174 (2000)		
71.	ВD	CHAUDHARY et al., The Human Retroviruses, Ch. 18, 379-387 (1991)		·

Examiner Signature		Date Considered		
	/Zachariah Lucas/	L pare considered	01/25/2007	
	/ Zacharian Lucas/	!	01/25/2007	
·			V T I I I I I I I I I I I I I I I I I I	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).





DT Dec'd PCT/PTO 1 0 NOV 2004

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

	Complete if Known
Application Number	Unassigned 4075,3901
Filing Date	Herewith
First Named Inventor	BOYD et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	231119

Examiner	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher city								
Initials	No.	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	slation No*					
7.1.	BE	CHAUDHARY et al., <i>Nature</i> , 335, 369-372 (1988)							
	BF	CLANTON et al., J. Acquired Immune Deficiency Syndromes, 5, 771-781 (1992)							
	BG	COFFIN, Science, 267, 483-489 (1995)							
	вн	COHEN, Science, 267, 179 (1995)							
	ВΙ	CRESSWELL et al., Algal and Cyanobacterial Biotechnology, 211-218 (1989)							
	ВJ	DAVEY et al., J. Infect. Dis., 170, 1180-1188 (1994)							
	ВК	DAVIS, J. Pharm. Pharmacol., 44(Suppl. 1), 186-190 (1992)							
	BL	DE CLERCQ, Adv. In Virus Res., 42, 1-55 (1993)							
	вм	DE CLERCQ, J. Acquired Immune Deficiency Syndromes, 4(3), 207-218 (1991)							
	BN	DOES et al., Plant Mol. Biol., 39, 335-347 (1999)							
	ВО	DORSEY et al., Protease Inhibitors in AIDS Therapy, Ch. 4, 65-84 No Date Availab	.e						
	BP	DUNCAN et al., Protease Inhibitors in AIDS Therapy, Ch. 2, 27-48 No Date Availab							
	BQ								
BR									
	BS	FLINT et al., Virlogy Molecular Biology, Pathogenesis, and Control, Ch. 19, 662-714							
		(2000)		ĺ					
	ВТ	FRANKMOLLE et al., J. Antibiotics, 45(9), 1451-1457 (1992)							
	ВU	FREED et al., Bull. Inst. Pasteur., 88, 73-110 (1990)							
	BV	FUNG et al., J. Immunology, 145(7), 2199-2206 (1990)							
	BW	GARTNER et al., Techniques in HIV Research, Ch. 3, 59-63 (1994)							
	вх	GULAKOWSKI et al., J. Virol. Methods, 33, 87-100 (1991)							
	BY	GUSTAFSON et al., J. Med. Chem., 35, 1978-1986 (1992)							
	ΒZ	HARATA et al., J. Mol. Biol., 297, 673-681 (2000)							
	CA	HILIER et al., Clin. Infect. Dis., 16(Suppl 4), S273-S281 (1993)							
	СВ	HOLS et al., Appl. and Environ. Microbiol., 60(5), 1401-1413 (1994)							
	СС	HUSSON et al., J. Pediatr., 121(4), 627-633 (1992)							
	CD	KASHMAN et al., J. Med. Chem., 35, 2735-2743 (1992)							
	CE	KEMPTF, Protease Inhibitors in AIDS Therapy, Ch. 3, 49-64 No Date Available							
	CF	KILBY et al., Nature Medicine, 4(11), 1302-1307 (1998)							
	CG	KRISHNAMURTHY et al., PNAS USA, 86, 770-774 (1989)							
	СН	LANGNER et al., Arch. Virol., 130, 157-170 (1993)							
	CI	LIFSON et al., J. Exp. Med., 164, 2101-2106 (1986)		·					
	CJ	LIN et al., Animicrob. Agents Chemother., 33(12), 2149-2151 (1989)							
	СК	LIOU et al., Biochemistry, 38, 11415-11424 (1999)							
	CL	LIPTON, Nature, 367, 113-114 (1994)							
	CM	MATSUSHITA et al., J. Virology, 62(6), 2107-2114 (1988)							
	CN	MCGROARTY, FEMS Immunol. Med. Microbiol., 6, 251-264 (1993)							
	CO	MERIGAN, Amer. J. Med., 90(Suppl. 4A), 8S-17S (1991)							
	CP	MICHALOWSKI et al., Nucleic Acids Res., 18(8), 2186 (1990)							
ZL	CQ	MITSUYA et al., Science, 249, 1533-1544 (1990)							

Examiner Signature	/Zachariah Lucas/	Date Considered	01/25/2007	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).





DT Rec'd PCT/PTO 1 0 NOV 2004

				Complete if Knawe LEAS A				
Substitute for fo	m 1449A/B/PTO			Application Number	Unassigned 513961			
INIE	DRMATION I		agupa r	Filing Date	Herewith			
				First Named Inventor	BOYD et al.			
SIA	tement by	T AP	PLICANI	Group Art Unit	Unassigned			
	(Use as many sheet	s as ne	cessary)	Examiner Name	Unassigned			
Sheet	3	of	3	Attorney Docket Number	231119			

Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,	Tran	slation					
Initials	No.	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*					
ZL	CR	MOORE et al., J. Virology, 66(1), 235-243 (1992)	_						
	CS	MORGAN et al., AIDS Research and Human Retroviruses, 10(11), 1507-1515 (1994)							
	CT	OKINO et al., Tetrahedron Ltrs., 34(3), 501-504 (1993)							
	CU	ORLOFF et al., AIDS Research and Human Retroviruses, 11(3), 335-342 (1995)							
	CV	PATTERSON et al., <i>J. Phycol.</i> , 27, 530-536 (1991)							
	CW	PATTERSON et al., J. Phycol., 29, 125-130 (1993)							
	СХ	POLSKY et al., Contraception, 39(6), 579-587 (1989)							
	CY	RAMACHANDRAN et al., JID, 170, 1009-1013 (1994)							
	CZ	REDONDO-LOPEZ et al., Reviews Infect. Dis., 12(5), 856-872 (1990)							
	DA	REICH, Protease Inhibitors in AIDS Therapy, Ch. 5, 85-99 No Date Available							
DB DC		REID et al., Clinical Microbiol. Reviews, 3(4), 335-344 (1990)							
	DE								
	DF								
DO		SATTENTAU et al., AIDS, 2(2), 101-105 (1988)							
	DH	SCHAEFFER et al., Ecotoxicology and Evironmental Safety, 45, 208-227 (2000)							
	DI	SCHOOLEY et al., Annals of Internal Medicine, 112(4), 247-253 (1990)							
	DJ	SHENOY et al., J. Pharmacol. Exp. Ther., 297(2), 704-710 (2001)							
	DK	SHERMAN et al., The Cyanobacteria, Ch. 1, 1-33 (1987)							
	DL	SHIH et al., PNAS USA, 88, 9878-9882 (1991)							
	DM	SIVONEN et al., Chem. Res. Toxicol., 5(4), 464-469 (1992)							
	DN	SUTER et al., FEBS Ltrs., 217(2), 279-282 (1987)							
	DO	SWANSON et al., J. Biol. Chem., 267(23) 16146-16154 (1992)							
	DP	TAYLOR, J. NIH Res., 6, 26-27 (1994)							
	DQ	THEIβ et al., Meth. Find. Exp. Clin. Pharmacol., 13(5), 353-359 (1991)							
	DR	TILL et al., Science, 242, 1166-1168 (1988)							
	DS	TRAUNECKER et al., Nature, 339, 68-70 (1989).							
	DT	TUNG et al., Protease Inhibitors in AIDS Therapy, Ch. 6, 101-118 No Date Availab	е						
	DU	VERHOEF et al., Eur. J. Drug Metab. Phartmacokinet., 15(2), 83-93 (1990)							
	DV	WALLACE et al., Science, 260, 912-913 (1993)							
	DW	WEISLOW et al., J. Natl. Cancer Inst., 81(8), 577-586 (1989)		~					
	DX	WHITE et al., Antiviral Res., 16, 257-266 (1991)							
	DY	WUNSCH, Biopolymers, 22, 493-505 (1983)							
	D.Z	YEH et al., PNAS USA, 89, 1904-1908 (1992)							
ZL	EΑ	ZAGHOUANI et al., PNAS USA, Vol. 88, 5645-5649 (1991)							
	•								

Examiner Signature	/Zachariah Lucas/	Date Considered	01/25/2007	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).